Skip to main content
Clinical Trials/NCT00556465
NCT00556465
Completed
Phase 2

Study of N-Acetylcysteine for Treatment of Overt Diabetic Nephropathy

Shiraz University of Medical Sciences1 site in 1 country60 target enrollmentJanuary 2007

Overview

Phase
Phase 2
Intervention
N-acetylcysteine
Conditions
Diabetic Nephropathy
Sponsor
Shiraz University of Medical Sciences
Enrollment
60
Locations
1
Primary Endpoint
Proteinuria
Status
Completed
Last Updated
18 years ago

Overview

Brief Summary

Diabetic nephropathy has become the single most frequent cause of end-stage renal disease.

On a molecular level, at least five major pathways have been implicated in glucose-mediated vascular and renal damage and all of these could reflect a single hyperglycaemia-induced process of overproduction of reactive oxygen species.

Recent studies have shown that inflammation, and more specifically pro-inflammatory cytokines play a determinant role in the development of micro- vascular diabetic complications, most of the attention has been focused on the implications of TNF-α in the setting of diabetic nephropathy.

Glutathione is the most abundant low-molecular-weight thiol, and Glutathione/ glutathione disulfide is the major redox couple in animal cells.

N-acetylcysteine is effective precursors of cysteine for tissue Glutathione synthesis.

Not only does N-acetylcysteine exhibit antioxidant properties, but it may also counteract the glycation cascade through the inhibition of oxidation.

N-acetylcysteine can also reduce the apoptosis elicited by reactive oxygen species .

Indeed, N-acetylcysteine has been shown to inhibit reactive oxygen species induced mesangial apoptosis and to be able to protect cells from glucose-induced inhibition of proliferation.

Registry
clinicaltrials.gov
Start Date
January 2007
End Date
June 2007
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Diabetic patients with more than 500 mg protein in 24 hours urine protein sample
  • Males and post-menopausal non-lactating and non-pregnant females.
  • Age greater than or equal to 30 years of age.
  • Serum creatinine less than 3.0 mg/dL (265 micromoles per liter)
  • Willing and able to give informed consent

Exclusion Criteria

  • Type 1 (insulin-dependent; juvenile onset) diabetes
  • Patients with known non-diabetic renal disease
  • Renal allograft
  • Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 3 months of study entry
  • Cerebrovascular accident within 3 months of study entry
  • New York Heart Association Functional Class III or IV
  • Known allergies or intolerance to N-acetylcysteine
  • Untreated urinary tract infection or other medical condition that may impact urine protein values.

Arms & Interventions

A, 1,III

in this arm patients took 1200 mg N-acetylcysteine

Intervention: N-acetylcysteine

Outcomes

Primary Outcomes

Proteinuria

Time Frame: 3 months

Secondary Outcomes

  • blood pressure,serum creatinine,GFR,c-reactive protein,(3 months)

Study Sites (1)

Loading locations...

Similar Trials